Evidence map›Paper›PMID 26401087›Full record

ArticleWorld journal of gastroenterology2015

Changes of shear-wave velocity by interferon-based therapy in chronic hepatitis C.

Keisuke Osakabe, Naohiro Ichino, Toru Nishikawa, Hiroko Sugiyama, Miho Kato, Ai Shibata, Wakana Asada, Naoto Kawabe, Senju Hashimoto, Michihito Murao and 9 more

Abstract readEvaluation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of gastroenterology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Keisuke OsakabeKeisuke Osakabe, Naohiro Ichino, Faculty of Medical Technology, School of Health Sciences, Fujita Health University, Kutsukake, Toyoake, Aichi 470-1192, Japan.
Naohiro IchinoKeisuke Osakabe, Naohiro Ichino, Faculty of Medical Technology, School of Health Sciences, Fujita Health University, Kutsukake, Toyoake, Aichi 470-1192, Japan.
Toru NishikawaKeisuke Osakabe, Naohiro Ichino, Faculty of Medical Technology, School of Health Sciences, Fujita Health University, Kutsukake, Toyoake, Aichi 470-1192, Japan.
Hiroko SugiyamaKeisuke Osakabe, Naohiro Ichino, Faculty of Medical Technology, School of Health Sciences, Fujita Health University, Kutsukake, Toyoake, Aichi 470-1192, Japan.
Miho KatoKeisuke Osakabe, Naohiro Ichino, Faculty of Medical Technology, School of Health Sciences, Fujita Health University, Kutsukake, Toyoake, Aichi 470-1192, Japan.
Ai ShibataKeisuke Osakabe, Naohiro Ichino, Faculty of Medical Technology, School of Health Sciences, Fujita Health University, Kutsukake, Toyoake, Aichi 470-1192, Japan.
Wakana AsadaKeisuke Osakabe, Naohiro Ichino, Faculty of Medical Technology, School of Health Sciences, Fujita Health University, Kutsukake, Toyoake, Aichi 470-1192, Japan.
Naoto KawabeKeisuke Osakabe, Naohiro Ichino, Faculty of Medical Technology, School of Health Sciences, Fujita Health University, Kutsukake, Toyoake, Aichi 470-1192, Japan.
Senju HashimotoKeisuke Osakabe, Naohiro Ichino, Faculty of Medical Technology, School of Health Sciences, Fujita Health University, Kutsukake, Toyoake, Aichi 470-1192, Japan.
Michihito MuraoKeisuke Osakabe, Naohiro Ichino, Faculty of Medical Technology, School of Health Sciences, Fujita Health University, Kutsukake, Toyoake, Aichi 470-1192, Japan.
Takuji NakanoKeisuke Osakabe, Naohiro Ichino, Faculty of Medical Technology, School of Health Sciences, Fujita Health University, Kutsukake, Toyoake, Aichi 470-1192, Japan.
Hiroaki ShimazakiKeisuke Osakabe, Naohiro Ichino, Faculty of Medical Technology, School of Health Sciences, Fujita Health University, Kutsukake, Toyoake, Aichi 470-1192, Japan.
Toshiki KanKeisuke Osakabe, Naohiro Ichino, Faculty of Medical Technology, School of Health Sciences, Fujita Health University, Kutsukake, Toyoake, Aichi 470-1192, Japan.
Kazunori NakaokaKeisuke Osakabe, Naohiro Ichino, Faculty of Medical Technology, School of Health Sciences, Fujita Health University, Kutsukake, Toyoake, Aichi 470-1192, Japan.
Yuka TakagawaKeisuke Osakabe, Naohiro Ichino, Faculty of Medical Technology, School of Health Sciences, Fujita Health University, Kutsukake, Toyoake, Aichi 470-1192, Japan.
Masashi OhkiKeisuke Osakabe, Naohiro Ichino, Faculty of Medical Technology, School of Health Sciences, Fujita Health University, Kutsukake, Toyoake, Aichi 470-1192, Japan.
Takamitsu KurashitaKeisuke Osakabe, Naohiro Ichino, Faculty of Medical Technology, School of Health Sciences, Fujita Health University, Kutsukake, Toyoake, Aichi 470-1192, Japan.
Tomoki TakamuraKeisuke Osakabe, Naohiro Ichino, Faculty of Medical Technology, School of Health Sciences, Fujita Health University, Kutsukake, Toyoake, Aichi 470-1192, Japan.
Kentaro YoshiokaKeisuke Osakabe, Naohiro Ichino, Faculty of Medical Technology, School of Health Sciences, Fujita Health University, Kutsukake, Toyoake, Aichi 470-1192, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo evaluate the changes of shear-wave velocity (Vs) by acoustic radiation force impulse after treatment in chronic hepatitis C.

methodsEighty-seven patients with chronic hepatitis C were consecutively treated with combinations of interferon (IFN) plus ribavirin (RBV). Vs value (m/s) was measured with acoustic radiation force impulse before treatment, at end of treatment (EOT), 1 year after EOT, and 2 years after EOT.

resultsIn patients with a sustained virological response (SVR) (n = 41), Vs significantly decreased at EOT [1.19 (1.07-1.37), P = 0.0004], 1 year after EOT [1.10 (1.00-1.22), P = 0.0001], and 2 years after EOT [1.05 (0.95-1.16), P < 0.0001] compared with baseline [1.27 (1.11-1.49)]. In patients with a relapse (n = 26), Vs did not significantly decrease at EOT [1.23 (1.12-1.55)], 1 year after EOT [1.20 (1.12-1.80)], and 2 years after EOT [1.41 (1.08-2.01)] compared with baseline [1.39 (1.15-1.57)]. In patients with a nonvirological response (n = 20), Vs did not significantly decrease at EOT [1.64 (1.43-2.06)], 1 year after EOT [1.66 (1.30-1.95)], and 2 years after EOT [1.61 (1.36-2.37)] compared with baseline [1.80 (1.54-2.01)]. Among genotype 1 patients, baseline Vs was significantly lower in SVR patients [1.28 (1.04-1.40)] than in non-SVR patients [1.56 (1.20-1.83)] (P = 0.0142).

conclusionReduction of Vs values was shown in SVR patients after IFN-plus-RBV therapy by acoustic radiation force impulse.

Indexed as

Elasticity Imaging TechniquesAdultAgedAntiviral AgentsDrug Therapy, CombinationFemaleHepatitis C, ChronicHumansInterferon-alphaInterferon alpha-2LiverLiver CirrhosisMaleMiddle AgedPolyethylene GlycolsPredictive Value of TestsAntiviral AgentsInterferon-alphaInterferon alpha-2peginterferon alfa-2apeginterferon alfa-2bPolyethylene GlycolsRecombinant ProteinsRibavirinFibrosisHepatitis C virusInterferon and ribavirinLiver stiffnessShear-wave velocity

Identifiers

PMID26401087
PMCPMC4572803

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.